Search

Displaying results 6631 - 6640 of 7059 in total
  1. Drug

    ING-1

    go.drugbank.com/drugs/DB05831
    Investigational

    ING-1 is a high-affinity, human engineered trade mark monoclonal antibody that recognizes a 40 kilodalton epithelial cell adhesion molecule (EpCAM) glycoprotein that is expressed in high levels on most

  2. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  3. Drug

    Elsibucol

    go.drugbank.com/drugs/DB05840
    Experimental

    AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common

  4. Drug

    BI-K0376

    go.drugbank.com/drugs/DB05858
    Experimental

    BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.

  5. Drug

    PPI-2458

    go.drugbank.com/drugs/DB05864
    Investigational

    PPI-2458 represents a potentially new and important addition to the growing list of therapeutics aimed at specific molecular oncology targets. … PPI-2458 is a novel, proprietary molecule belonging to the fumagillin class of compounds that specifically targets the MetAP-2 enzyme.

  6. Drug

    AVI-4020

    go.drugbank.com/drugs/DB05873
    Investigational

    AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).

  7. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

  8. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    CHF 4227 is a new selective estrogen receptor modulator (SERM). … The compound has a high receptor affinity and has shown promising efficacy in the prevention of bone loss in animal models of osteoporosis.

  9. Drug

    TAFA-93

    go.drugbank.com/drugs/DB05887
    Experimental

    , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary artery disease. … TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation

  10. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.